Classes
DEA Class; Rx
Common Brand Names; Surmontil, Trimip, Tripramine
- Antidepressants, TCAs
Description
Tertiary amine tricyclic antidepressant (TCA), considerable sedative and anxiolytic effects
FDA-approved to treat major depression in adult patients; especially useful for those with co-existing sleep disturbances or anxiety
Boxed warning for use in pediatric patients and young adults due to risk for suicidality
Indications
Indicated for the treatment of major depression.
Contraindications
Hypersensitivity
Severe cardiovascular disorder
Narrow angle glaucoma
Any drugs or conditions that prolong QT interval
Acute recovery post-MI
Adverse Effects
- Sedation (less than amitriptyline, but greater than imipramine)
- Fatigue
- Dry mouth
- Constipation
- Blurred vision
- Weakness
- Lethargy
- Headache
- Agitation
- Insomnia
- Nausea/vomiting
- Anxiety
- Sweating
- Confusion
- EPS
- Dizziness
- Tinnitus
- Paresthesia
- Orthostatic hypotension
- ECG changes
- Tachycardia
- Incr LFTs
- Sexual dysfunction
- Rash
- Seizure (rare)
- Agranulocytosis, thrombocytopenia, eosinophilia, leukopenia (rare)
- SIADH (rare)
Warnings
BPH, urinary/GI retention, increases IOP, hyperthyroidism, open-angle glaucoma, seizure disorder, brain tumor, respiratory impairment
Clinical worsening and suicide ideation may occur despite medication
Risk of anticholinergic side-effects
Risk of mydriasis; may trigger angle closure attack in patients with angle closure glaucoma with anatomically narrow angles without a patent iridectomy
Pregnancy and Lactation
Pregnancy Category: C
Lactation: avoid
Maximum Dosage
200 mg/day PO in outpatients; 300 mg/day PO in hospitalized patients.
100 mg/day PO.
100 mg/day PO.
Safety and efficacy have not been established.
How supplied
Trimipramine maleate
capsule
- 25mg
- 50mg
- 100mg